

Patient characteristics to guide IV iron product of choice		
Age:	16 - 18 years	Ferinject[®] 1
Weight:	35 - 49kg	Monofer[®] 2
Weight:	75 - 99kg	Monofer[®] 2
Hb:	100 - 130g/L	
Weight:	>100kg	Monofer[®] 2
Risk factors for hypophosphataemia* requiring multiple high-dose infusions / long-term treatment		Monofer[®] 3
Reason: 1 Licensed for use in >14 years. 2 Reduced number of weekly infusion(s) required to administer as total dose infusion. 3 The risk of persistent hypophosphatemia and osteomalacia may be higher with Ferinject [®] than with other IV iron formulations (see MHRA drug safety update Ferric carboxymaltose (Ferinject[®]): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures) *vitamin D deficiency, calcium and phosphate malabsorption, secondary hyperparathyroidism, inflammatory bowel disease and osteoporosis.		